Home / Business / Vaccine maker Covid CureVac hopes the shot will receive EU approval in June.

Vaccine maker Covid CureVac hopes the shot will receive EU approval in June.

A man pipette a blue liquid in a laboratory for biopharmaceutical company Curevac.

Sebastian Golowe | Alliance Images | Getty Images

CureVac, maker of the coronavirus vaccine, said it hoped the coronavirus would receive European approval in the second quarter.

CureVac CEO Franz-Werner Haas told CNBC on Thursday that the vaccine maker was close to finalizing the recruitment for a Phase 3 clinical trial of the vaccine.He said approval could come shortly due to the accelerated need. Prompt for more efficient coronavirus vaccination and a regulatory approval process.

“We expect, based on our calculations, that in late April or early May we will have data,”

; Haas told CNBC’s Squawk Box Europe.

“So we expect approval depending on the exact data in early June”

When trials are underway, German biotech CureVac waits for safety data and then analyzes the interim results from the late studies. It is also important to wait until a number of trial participants develop Covid-19 to see how effective the vaccine is to protect against the virus.

The information is then sent to regulators such as the European Medicines Agency for the so-called. This is information analyzed by regulators as they accelerate the evaluation of potentially life-saving vaccines or drugs or drugs in public health emergencies.

Up to 455 million doses of CureVac’s mRNA vaccine were pre-ordered by the UK and EU, subject to regulatory approvals.The company is already producing the vaccine, although it hasn’t been approved yet pending approval from the shooter.

CureVac CEO Haas said the company was trying to avoid a production error that was affected by other vaccine makers. This issue is perhaps the most noticeable on AstraZeneca, and has clearly mitigated the vulnerability of the global supply chain.

“Production is definitely a struggle right now,” he said.

“Not just the production itself. But we have a whole network in Europe, with other companies supporting us in production there too. But sometimes it is very difficult to get a device to get a facility built, but also a material to produce mRNA.

“But we’re doing everything we can to get the most volume possible,” Haas added.

Source link